A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
But for some, the claims by Vertex Pharmaceuticals that Journavx is not habit-forming, unlike opioid painkillers, leaves them a bit skeptical — it's something they've heard before, from the ...
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results